

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

U.S. PATENT DOCUMENTS

| **Examiner Initial | Document Number | Date | Name | Class | Subclass | Filing Date If Appropriate |
|-----------------------|-----------------|------------|----------------------|-------|----------|-------------------------------|
| <i>ll</i> | 2,914,563 | 11/24/1959 | Allen et al. | 260 | 570 | 08/06/57 |
| | 3,010,965 | 11/28/1961 | Elpern | 260 | 293 | 02/05/57 |
| | 3,168,565 | 02/02/1965 | Palopoli et al. | 260 | 570.7 | 11/20/59 |
| | 3,288,806 | 11/29/1966 | DeWald et al. | 260 | 326.5 | 03/23/64 |
| | 3,634,517 | 01/11/1972 | Palopoli et al. | 260 | 590 | 08/19/68 |
| | 3,940,422 | 02/24/1976 | Harita et al. | 260 | 340 | 01/17/74 |
| | 4,070,484 | 01/24/1978 | Harita et al. | 424 | 319 | 12/21/76 |
| | 4,093,709 | 06/06/1978 | Sok Choi et al. | 424 | 19 | 01/28/75 |
| | 4,133,814 | 01/09/1979 | Jones et al. | 260 | 326 | 09/17/76 |
| | 4,230,862 | 10/28/1980 | Suarez et al. | 546 | 237 | 08/03/78 |
| | 4,235,988 | 11/25/1980 | Fildes et al. | 528 | 79 | 05/31/79 |
| | 4,239,778 | 12/16/1980 | Venton et al. | 424 | 305 | 09/12/78 |
| | 4,307,111 | 12/22/1981 | Crawley | 424 | 278 | 04/29/80 |
| | 4,323,707 | 04/06/1982 | Suarez et al. | 564 | 324 | 05/12/80 |
| | 4,380,635 | 04/19/1983 | Peters | 546 | 324 | 05/12/80 |
| | 4,418,068 | 11/29/1983 | Jones | 424 | 267 | 12/16/81 |
| | 4,442,119 | 04/10/1984 | Magarian et al. | 424 | 274 | 07/26/82 |
| | 4,512,762 | 04/23/1985 | Spears | 604 | 21 | 11/23/82 |
| | 4,536,516 | 08/20/1985 | Harper | 514 | 574 | 04/17/84 |
| | 4,675,189 | 06/23/1987 | Kent et al. | 424 | 490 | 02/08/85 |
| | 4,696,949 | 08/29/1987 | Toivola et al. | 514 | 648 | 05/25/83 |
| | 4,824,436 | 04/25/1989 | Wolinsky | 604 | 53 | 04/21/87 |
| | 4,826,672 | 05/02/1989 | Milius et al. | 424 | 1 | 06/07/85 |
| | 4,835,002 | 05/30/1989 | Wolf et al. | 426 | 590 | 07/10/87 |
| | 4,839,155 | 06/13/1989 | Mccague | 424 | 1 | 09/09/87 |
| | 4,859,585 | 08/22/1989 | Sonnenschein et al. | 435 | 29 | 04/17/86 |
| | 4,879,315 | 11/07/1989 | Magarian et al. | 514 | 754 | 09/21/87 |
| | 4,929,602 | 05/29/1990 | Harker et al. | 514 | 18 | 11/22/88 |
| | 4,962,091 | 10/09/1990 | Eppstein et al. | 514 | 2 | 05/23/86 |
| | 4,968,350 | 11/06/1990 | Bindschaedler et al. | 106 | 170 | 04/01/88 |
| | 4,973,755 | 11/27/1990 | Grafe et al. | 564 | 324 | 04/19/88 |
| | 4,990,538 | 02/05/1991 | Harris et al. | 514 | 648 | 08/23/89 |
| | 4,994,033 | 02/19/1991 | Shockey et al. | 604 | 101 | 05/29/89 |
| | 4,996,225 | 02/26/1991 | Toivola et al. | 514 | 428 | 05/25/83 |
| | 4,997,652 | 03/05/1991 | Wong | 424 | 428 | 05/31/89 |
| | 5,008,279 | 04/16/1991 | Franckowiak et al. | 514 | 345 | 10/27/88 |
| | 5,009,659 | 04/23/1991 | Hamlin et al. | 606 | 159 | 10/30/89 |
| | 5,015,666 | 05/14/1991 | Magarian et al. | 514 | 754 | 09/22/89 |
| | 5,026,537 | 06/25/1991 | Daddona et al. | 424 | 1.1 | 05/06/89 |
| | 5,032,679 | 07/16/1991 | Brandley et al. | 536 | 21 | 08/31/89 |
| | 5,043,335 | 08/27/1991 | Kleinschroth et al. | 514 | 211 | 06/23/90 |
| | 5,047,431 | 09/10/1991 | Schickneder et al. | 514 | 648 | 05/14/90 |
| | 5,049,132 | 09/17/1991 | Schaffer et al. | 604 | 101 | 01/08/90 |
| | 5,053,033 | 10/01/1991 | Clarke et al. | 606 | 3 | 10/10/90 |

Examiner

Chafetz

Date Considered

6/22/07

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

U.S. PATENT DOCUMENTS

| **Examiner Initial | Document Number | Date | Name | Class | Subclass | Filing Date If Appropriate |
|-----------------------|-----------------|------------|-------------------|-------|----------|-------------------------------|
| UR | 5,059,166 | 11/22/1991 | Fischell et al. | 600 | 3 | 12/11/89 |
| | 5,066,789 | 11/19/1991 | Srinivasan et al. | 530 | 388 | 09/29/89 |
| | 5,075,321 | 12/24/1991 | Schreiber | 514 | 317 | 02/24/88 |
| | 5,098,903 | 03/24/1992 | Magarian et al. | 514 | 255 | 11/06/89 |
| | 5,102,402 | 04/07/1992 | Dror et al. | 604 | 265 | 01/04/91 |
| | 5,108,989 | 05/28/1992 | Amento et al. | 514 | 12 | 04/04/90 |
| | 5,112,305 | 05/12/1992 | Barath et al. | 704 | 96 | 10/16/90 |
| | 5,114,719 | 05/19/1992 | Sabel et al. | 424 | 422 | 09/14/89 |
| | 5,116,864 | 05/26/1992 | March et al. | 514 | 455 | 04/09/91 |
| | 5,120,535 | 06/09/1992 | Marquardt et al. | 424 | 85.5 | 05/04/87 |
| | 5,140,012 | 08/18/1992 | McGovern et al. | 514 | 19 | 05/31/90 |
| | 5,166,143 | 11/24/1992 | Ondetti et al. | 514 | 89 | 06/13/91 |
| | 5,171,217 | 12/15/1992 | March et al. | 604 | 53 | 02/28/91 |
| | 5,176,617 | 01/05/1993 | Fischell et al. | 600 | 3 | 11/21/91 |
| | 5,180,366 | 01/19/1993 | Woods | 604 | 96 | 10/10/90 |
| | 5,185,260 | 02/09/1993 | Crissman et al. | 435 | 244 | 08/29/91 |
| | 5,189,046 | 02/23/1993 | Burch et al. | 514 | 330 | 08/14/90 |
| | 5,189,212 | 02/23/1993 | Ruenitz | 562 | 468 | 09/07/90 |
| | 5,192,525 | 03/09/1993 | Yang et al. | 424 | 11 | 06/28/91 |
| | 5,199,939 | 04/06/1993 | Dake et al. | 600 | 3 | 02/23/90 |
| | 5,208,019 | 05/05/1993 | Hanson et al. | 424 | 85 | 09/27/89 |
| | 5,213,576 | 05/25/1993 | Abiuso et al. | 604 | 96 | 06/11/91 |
| | 5,213,580 | 05/25/1993 | Slepian et al. | 623 | 1 | 03/25/92 |
| | 5,216,126 | 06/01/1993 | Cox et al. | 530 | 350 | 06/19/91 |
| | 5,219,548 | 06/15/1993 | Yang et al. | 424 | 1 | 10/01/90 |
| | 5,221,620 | 06/22/1993 | Purchio et al. | 435 | 69 | 12/05/89 |
| | 5,226,430 | 07/13/1993 | Spears et al. | 128 | 898 | 05/24/91 |
| | 5,229,495 | 04/20/1993 | Ichijo et al. | 530 | 350 | 06/18/91 |
| | 5,232,444 | 08/03/1993 | Just et al. | 604 | 96 | 02/25/91 |
| | 5,238,714 | 08/24/1993 | Wallace et al. | 427 | 213 | 10/02/90 |
| | 5,238,950 | 08/24/1993 | Clader et al. | 514 | 360 | 12/17/91 |
| | 5,242,397 | 09/07/1993 | Barath et al. | 604 | 96 | 01/02/92 |
| | 5,248,764 | 09/28/1993 | Flanagan et al. | 530 | 324 | 02/27/92 |
| | 5,254,594 | 10/19/1993 | Niikura et al. | 514 | 648 | 04/08/92 |
| | 5,268,358 | 12/07/1993 | Fretto et al. | 514 | 12 | 05/06/91 |
| | 5,270,047 | 12/14/1993 | Kauffman et al. | 424 | 422 | 11/21/91 |
| | 5,280,016 | 01/18/1994 | Conrad et al. | 514 | 56 | 09/03/91 |
| | 5,280,109 | 01/18/1994 | Miyazono et al. | 530 | 399 | 01/27/92 |
| | 5,282,785 | 02/01/1994 | Shapland et al. | 604 | 21 | 10/05/92 |
| | 5,283,257 | 02/01/1994 | Gregory et al. | 514 | 458 | 07/10/92 |
| | 5,284,763 | 02/08/1994 | Derynk et al. | 435 | 240 | 03/04/92 |
| | 5,284,869 | 02/08/1994 | Bisaccia et al. | 514 | 455 | 12/17/91 |
| | 5,288,711 | 02/22/1994 | Mitchell et al. | 514 | 56 | 04/28/92 |
| ✓ | 5,296,492 | 03/22/1994 | Shiozawa et al. | 514 | 337 | 06/03/92 |

| | |
|----------------------------|-------------------------|
| Examiner <i>Ch. F. Lee</i> | Date Considered 6/21/07 |
|----------------------------|-------------------------|

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

U.S. PATENT DOCUMENTS

| **Examiner Initial | Document Number | Date | Name | Class | Subclass | Filing Date If Appropriate |
|-----------------------|-----------------|------------|-------------------|-------|----------|-------------------------------|
| <i>ck</i> | 5,304,325 | 04/19/1994 | Kaufman et al. | 252 | 312 | 11/13/91 |
| | 5,304,541 | 04/19/1994 | Purchio et al. | 514 | 12 | 03/14/91 |
| | 5,308,622 | 05/03/1994 | Casscells et al. | 424 | 422 | 07/16/92 |
| | 5,308,862 | 05/03/1994 | Ohlstein et al. | 514 | 411 | 03/05/93 |
| | 5,314,679 | 05/24/1994 | Lewis et al. | 424 | 9 | 12/22/92 |
| | 5,316,766 | 05/31/1994 | Baldus et al. | 424 | 94 | 02/06/90 |
| | 5,324,736 | 06/28/1994 | Magarin et al. | 514 | 317 | 08/16/93 |
| | 5,326,757 | 07/05/1994 | Demopoulos | 514 | 167 | 08/18/93 |
| | 5,328,471 | 07/12/1994 | Slepian | 604 | 101 | 08/04/93 |
| | 5,332,584 | 07/26/1994 | Scher et al. | 424 | 408 | 12/09/91 |
| | 5,340,925 | 08/23/1994 | Lioubin et al. | 530 | 395 | 06/17/92 |
| | 5,346,702 | 09/13/1994 | Na et al. | 424 | 490 | 12/04/92 |
| | 5,346,993 | 09/13/1994 | Miyazono et al. | 530 | 399 | 07/15/93 |
| | 5,354,562 | 10/11/1994 | Platz et al. | 424 | 489 | 01/16/93 |
| | 5,354,774 | 10/11/1994 | Deckelbaum et al. | 514 | 455 | 12/24/92 |
| | 5,354,801 | 10/11/1994 | O'Toole et al. | 524 | 461 | 08/12/93 |
| | 5,356,713 | 10/18/1994 | Charmot et al. | 428 | 407 | 06/01/93 |
| | 5,362,424 | 11/08/1994 | Lee et al. | 264 | 4.3 | 10/10/91 |
| | 5,364,632 | 11/15/1994 | Benita et al. | 424 | 450 | 03/09/93 |
| | 5,380,716 | 01/10/1995 | Conrad et al. | 514 | 56 | 12/28/92 |
| | 5,384,332 | 01/24/1995 | Fontana | 514 | 648 | 05/11/94 |
| | 5,385,935 | 01/31/1995 | Tamai et al. | 514 | 535 | 09/07/93 |
| | 5,389,670 | 02/14/1995 | Fontana | 514 | 443 | 12/21/93 |
| | 5,391,557 | 02/21/1995 | Cullinan et al. | 514 | 324 | 10/15/93 |
| | 5,393,763 | 02/28/1995 | Black et al. | 514 | 333 | 01/12/94 |
| | 5,393,772 | 02/28/1995 | Yue et al. | 514 | 410 | 11/24/93 |
| | 5,393,785 | 02/28/1995 | Labrie et al. | 514 | 622 | 07/14/92 |
| | 5,395,842 | 03/07/1995 | Labrie et al. | 514 | 320 | 12/02/91 |
| | 5,401,730 | 03/28/1995 | Sauvage et al. | 514 | 165 | 07/06/90 |
| | 5,418,252 | 05/23/1995 | Williams | 514 | 443 | 10/15/93 |
| | 5,423,885 | 06/13/1995 | Williams | 623 | 1 | 07/14/93 |
| | 5,424,331 | 06/13/1995 | Shlyankevich | 514 | 456 | 06/10/94 |
| | 5,426,123 | 06/20/1995 | Fontana | 514 | 651 | 05/11/94 |
| | 5,429,634 | 07/04/1995 | Narcisco Jr. | 604 | 890.1 | 09/09/93 |
| | 5,434,166 | 07/18/1995 | Glasebrook | 514 | 317 | 08/22/94 |
| | 5,436,243 | 07/25/1995 | Sachs et al. | 514 | 231 | 11/17/93 |
| | 5,439,923 | 08/08/1995 | Cullinan | 514 | 324 | 12/21/93 |
| | 5,439,931 | 08/08/1995 | Sales | 514 | 443 | 12/21/93 |
| | 5,441,947 | 08/15/1995 | Dodge et al. | 514 | 179 | 08/25/93 |
| | 5,441,964 | 08/15/1995 | Bryant et al. | 514 | 324 | 10/15/93 |
| | 5,441,965 | 08/15/1995 | Sall et al. | 514 | 324 | 12/21/93 |
| | 5,441,986 | 08/15/1995 | Thompson | 514 | 648 | 07/19/94 |
| <i>✓</i> | 5,444,164 | 08/22/1995 | Purchio et al. | 536 | 23.5 | 05/04/92 |
| | 5,446,053 | 08/29/1995 | Keohane | 514 | 324 | 12/21/93 |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

U.S. PATENT DOCUMENTS

| **Examiner Initial | Document Number | Date | Name | Class | Subclass | Filing Date If Appropriate |
|-----------------------|-----------------|------------|-------------------|-------|----------|-------------------------------|
| CR | 5,447,941 | 09/05/1995 | Zuckerman | 514 | 324 | 12/21/93 |
| | 5,453,442 | 09/26/1995 | Bryant et al. | 514 | 408 | 02/18/94 |
| | 5,455,275 | 10/03/1995 | Fontana | 514 | 648 | 05/11/94 |
| | 5,457,113 | 10/10/1995 | Cullinan et al. | 514 | 319 | 10/15/93 |
| | 5,457,116 | 10/10/1994 | Black et al. | 514 | 324 | 10/15/93 |
| | 5,457,117 | 10/10/1995 | Black et al. | 514 | 337 | 10/26/94 |
| | 5,458,568 | 10/17/1995 | Racchini et al. | 604 | 19 | 09/17/93 |
| | 5,462,937 | 10/31/1995 | Cullinan et al. | 514 | 212 | 04/14/95 |
| | 5,466,810 | 11/14/1995 | Godfrey | 546 | 202 | 06/10/94 |
| | 5,468,746 | 11/21/1995 | Casagrande et al. | 514 | 235.5 | 06/21/91 |
| | 5,470,883 | 11/28/1995 | Stromberg | 514 | 648 | 05/23/94 |
| | 5,472,985 | 12/05/1995 | Grainger et al. | 514 | 651 | 09/02/94 |
| | 5,478,847 | 12/26/1995 | Draper | 514 | 333 | 03/02/94 |
| | 5,480,888 | 01/02/1996 | Kodama et al. | 514 | 320 | 06/11/94 |
| | 5,480,904 | 01/02/1996 | Bryant et al. | 514 | 443 | 10/28/93 |
| | 5,482,949 | 01/09/1996 | Black et al. | 514 | 324 | 03/19/93 |
| | 5,482,950 | 01/09/1996 | Bryant et al. | 514 | 324 | 10/15/93 |
| | 5,484,795 | 01/16/1996 | Bryant et al. | 514 | 319 | 09/20/94 |
| | 5,484,796 | 01/16/1996 | Bryant et al. | 514 | 319 | 04/21/95 |
| | 5,484,798 | 01/16/1996 | Bryant et al. | 514 | 324 | 09/20/94 |
| | 5,484,808 | 01/16/1996 | Grinnell | 514 | 443 | 02/09/95 |
| | 5,489,587 | 02/06/1996 | Fontana | 514 | 233.5 | 01/20/95 |
| | 5,491,159 | 02/13/1996 | Malamas | 514 | 374 | 08/30/94 |
| | 5,491,173 | 02/13/1996 | Toivola et al. | 514 | 648 | 05/25/83 |
| | 5,492,921 | 02/20/1996 | Bryant et al. | 514 | 324 | 09/20/94 |
| | 5,492,922 | 02/20/1996 | Palkowitz | 514 | 324 | 02/28/95 |
| | 5,492,926 | 02/20/1996 | Cullinan et al. | 514 | 422 | 10/15/93 |
| | 5,492,927 | 02/20/1996 | Gitter et al. | 514 | 443 | 12/21/93 |
| | 5,496,828 | 03/05/1996 | Cullinan | 514 | 324 | 08/22/94 |
| | 5,498,775 | 03/12/1996 | Novak et al. | 514 | 25 | 11/07/94 |
| | 5,508,292 | 04/16/1996 | Sall et al. | 514 | 324 | 04/14/95 |
| | 5,510,370 | 04/23/1996 | Hock et al. | 514 | 443 | 03/06/95 |
| | 5,516,781 | 05/14/1996 | Morris et al. | 514 | 291 | 05/12/94 |
| | 5,516,807 | 05/14/1996 | Hupe et al. | 514 | 673 | 10/25/94 |
| | 5,519,042 | 05/21/1996 | Morris et al. | 514 | 378 | 01/13/94 |
| | 5,521,171 | 05/28/1996 | Sorenson | 514 | 188 | 03/24/95 |
| | 5,521,191 | 05/28/1996 | Greenwald | 514 | 262 | 10/17/94 |
| | 5,521,198 | 05/28/1996 | Zuckerman | 514 | 324 | 12/21/93 |
| | 5,527,337 | 06/18/1996 | Stack et al. | 606 | 198 | 02/01/91 |
| | 5,534,527 | 07/09/1996 | Black et al. | 514 | 333 | 04/14/95 |
| | 5,541,174 | 07/30/1996 | Sorenson | 514 | 186 | 01/18/95 |
| | 5,545,409 | 08/13/1996 | Laurencin et al. | 424 | 426 | 04/05/94 |
| | 5,545,569 | 08/13/1996 | Grainger et al. | 436 | 518 | 05/25/95 |
| | 5,552,415 | 09/03/1996 | May | 514 | 324 | 12/21/93 |

Examiner


Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

U.S. PATENT DOCUMENTS

| **Examiner Initial | Document Number | Date | Name | Class | Subclass | Filing Date If Appropriate |
|---|-----------------|------------|-----------------|-------|----------|-------------------------------|
|  | 5,567,713 | 10/22/1996 | Cullinan et al. | 514 | 324 | 01/09/95 |
| | 5,563,054 | 10/08/1996 | Briggs et al. | 435 | 127 | 03/31/95 |
| | 5,571,714 | 11/05/1996 | Dasch et al. | 435 | 240.27 | 12/22/88 |
| | 5,574,047 | 11/12/1996 | Bumol et al. | 514 | 324 | 12/21/93 |
| | 5,595,722 | 01/21/1997 | Grainger et al. | 424 | 9.2 | 06/07/95 |
| | 5,597,578 | 01/28/1997 | Brown et al. | 424 | 422 | 09/11/89 |
| | 5,599,844 | 02/04/1997 | Grainger et al. | 514 | 651 | 09/15/95 |
| | 5,610,166 | 03/11/1997 | Singh | 514 | 324 | 03/22/95 |
| | 5,622,975 | 04/22/1997 | Singh et al. | 514 | 324 | 06/01/95 |
| | 5,639,274 | 06/17/1997 | Fischell et al. | 604 | 96 | 06/02/95 |
| | 5,658,927 | 08/19/1997 | Magarian et al. | 514 | 315 | 06/07/95 |
| | 5,681,835 | 10/28/1997 | Willson | 514 | 237.5 | 04/25/94 |
| | 5,686,467 | 11/11/1997 | Bumol et al. | 514 | 324 | 03/15/95 |
| | 5,726,186 | 03/10/1998 | Grese | 514 | 321 | 08/13/96 |
| | 5,770,609 | 06/23/1998 | Grainger et al. | 514 | 319 | 06/07/95 |
| | 5,847,007 | 12/08/1998 | Grainger et al. | 514 | 651 | 05/12/94 |
| | 5,945,456 | 08/31/1999 | Grainger et al. | 514 | 651 | 11/06/97 |
| | Re. 32,944 | 06/06/1989 | Harita et al. | 562 | 455 | 06/01/77 |

FOREIGN PATENT DOCUMENTS

| **Examiner Initial | Document Number | Date | Country | Class | Subclass | Translation Yes No |
|-----------------------|-----------------|------------|---------------|-------|----------|-------------------------|
| | 0 054 168 | 06/23/1982 | European | C07C | 93/06 | Abstract |
| | 0 095 875 | 12/07/1983 | European | C07C | 33/26 | |
| | 0 260 066 | 03/16/1988 | European | C07C | 217/54 | |
| | 0 365 863 | 05/02/1990 | European | C07D | 413/54 | |
| | 0 374 044 | 06/20/1990 | European | C12N | 15/16 | |
| | 0 451 202 | 10/16/1991 | European | A61K | 9/70 | |
| | 0 542 679 | 05/19/1993 | European | C12N | 15/12 | |
| | 0 577 215 | 01/05/1993 | European | A61K | 9/14 | |
| | 0 584 952 | 03/02/1994 | European | A61K | 31/445 | |
| | 0 588 518 | 02/23/1994 | European | A61K | 31/165 | |
| | 0 606 613 | 07/20/1994 | European | G01N | 33/531 | |
| | 0 622 076 | 11/02/1994 | European | A61K | 31/165 | |
| | 0 629 697 | 12/21/1994 | European | C12N | 15/63 | |
| | 0 635 270 | 01/25/1995 | European | A61K | 38/29 | |
| | 0 664 121 | 07/26/1995 | European | A61K | 31/445 | |
| | 0 664 122 | 07/26/1995 | European | A61K | 31/445 | |
| | 0 670 162 | 09/06/1995 | European | A61K | 31/445 | |
| | 0 674 903 | 10/04/1995 | European | A61K | 31/445 | |
| | 0 675 121 | 10/04/1995 | European | C07D | 333/56 | |
| | 0 699 673 | 03/06/1996 | European | C07D | 333/56 | |
| | 1 015 787 | 01/05/1966 | Great Britain | | | |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

FOREIGN PATENT DOCUMENTS

| Examiner Initial | Document Number | Date | Country | Class | Subclass | Translation | |
|---------------------|-----------------|------------|---------------|-------|----------|-------------|----|
| | | | | | | Yes | No |
| | 2 273 873 | 06/07/1994 | Great Britain | A61K | 31/48 | | |
| | 4 320 896 | 01/05/1995 | Germany | A61K | 31/40 | | |
| | 4 320 898 | 01/05/1995 | Germany | A61K | 31/135 | | |
| | 4 401 554 | 08/18/1994 | Germany | A61K | 31/135 | | |
| | 85/00107 | 01/17/1985 | PCT | A61K | 31/13 | | |
| | 88/10259 | 12/29/1988 | PCT | C07D | 313/00 | | |
| | 90/01969 | 03/08/1990 | PCT | A61M | 29/00 | | |
| | 90/13293 | 11/15/1990 | PCT | A61K | 31/40 | | |
| | 91/15219 | 10/14/1991 | PCT | A61K | 37/00 | | |
| | 91/15222 | 10/17/1991 | PCT | A61K | 37/02 | | |
| | 92/06068 | 04/16/1992 | PCT | C07C | 217/18 | | |
| | 92/08480 | 05/29/1992 | PCT | A61K | 37/36 | | |
| | 92/11890 | 07/23/1992 | PCT | A61M | 25/00 | | |
| | 92/11895 | 07/23/1992 | PCT | A61K | 31/00 | | |
| | 92/18546 | 10/29/1992 | PCT | C08B | 37/10 | | |
| | 92/19273 | 11/12/1992 | PCT | A61K | 49/02 | | |
| | 92/19612 | 11/12/1992 | PCT | C07D | 333/38 | | |
| | 92/21363 | 12/10/1992 | PCT | A61K | 37/02 | | |
| | 93/07748 | 04/29/1993 | PCT | A01N | 43/16 | | |
| | 93/09228 | 05/13/1993 | PCT | C12N | 15/12 | | |
| | 93/09790 | 05/27/1993 | PCT | A61K | 31/70 | | |
| | 93/10808 | 06/10/1993 | PCT | A61K | 37/02 | | |
| | 93/11757 | 06/24/1993 | PCT | A61K | 31/135 | | |
| | 93/16724 | 09/02/1993 | PCT | A61K | 39/00 | | |
| | 93/19746 | 10/14/1993 | PCT | A61K | 31/135 | | |
| | 94/04164 | 03/03/1994 | PCT | A61K | 31/795 | | |
| | 94/04178 | 03/03/1994 | PCT | A61K | 37/02 | | |
| | 94/07529 | 04/14/1994 | PCT | A61K | 39/00 | | |
| | 94/08604 | 04/28/1994 | PCT | A61K | 37/00 | | |
| | 94/08605 | 04/28/1994 | PCT | A61K | 37/00 | | |
| | 94/09764 | 05/11/1994 | PCT | A61K | 31/00 | | |
| | 94/09812 | 05/11/1994 | PCT | A61K | 37/36 | | |
| | 94/10187 | 05/11/1994 | PCT | C07H | 21/02 | | |
| | 94/15589 | 07/21/1994 | PCT | A61K | 9/50 | | |
| | 94/15590 | 07/21/1994 | PCT | A61K | 9/51 | | |
| | 94/15646 | 07/21/1994 | PCT | A61K | 48/00 | | |
| | 94/16706 | 08/04/1994 | PCT | A61K | 31/535 | | |
| | 94/17786 | 08/18/1994 | PCT | A61K | 9/16 | | |
| | 94/18967 | 09/01/1994 | PCT | A61K | 31/415 | | |
| | 94/18968 | 09/01/1994 | PCT | A61K | 31/415 | | |
| | 94/19000 | 09/01/1994 | PCT | A61K | 37/02 | | |
| | 94/19001 | 09/01/1994 | PCT | A61K | 37/02 | | |
| | 94/19003 | 09/01/1994 | PCT | A61K | 37/02 | | |
| | 94/20096 | 09/15/1994 | PCT | A61K | 31/40 | | |
| | 94/20097 | 09/15/1994 | PCT | A61K | 31/40 | | |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

FOREIGN PATENT DOCUMENTS

| **Examiner Initial | Document Number | Date | Country | Class | Subclass | Translation | |
|-----------------------|-----------------|------------|---------|-------|----------|-------------|----|
| | | | | | | Yes | No |
| | 94/20126 | 09/15/1994 | PCT | A61K | 37/02 | | |
| | 94/20127 | 09/15/1994 | PCT | A61K | 37/02 | | |
| | 94/21679 | 09/29/1994 | PCT | C07K | 13/00 | | |
| | 94/23068 | 10/13/1994 | PCT | C12Q | 1/68 | | |
| | 94/23699 | 10/27/1994 | PCT | A61K | 9/14 | | |
| | 94/25588 | 11/10/1994 | PCT | C12N | 15/11 | | |
| | 94/26291 | 11/24/1994 | PCT | A61K | 37/02 | | |
| | 94/26303 | 11/24/1994 | PCT | A61K | 39/00 | | |
| | 94/26888 | 10/06/1995 | PCT | C12N | 15/11 | | |
| | 94/28721 | 12/22/1994 | PCT | A01N | 43/42 | | |
| | 95/03036 | 02/02/1995 | PCT | A61K | 9/16 | | |
| | 95/04544 | 02/16/1995 | PCT | A61K | 38/22 | | |
| | 95/10611 | 04/20/1995 | PCT | C12N | 15/12 | | |
| | 95/19987 | 07/27/1995 | PCT | C07H | 21/00 | | |
| | 95/30900 | 11/16/1995 | PCT | G01N | 33/50 | | |
| | 96/01102 | 01/18/1996 | PCT | A61K | 9/06 | | |
| | 96/07402 | 03/14/1996 | PCT | A61K | 31/075 | | |
| | 96/15224 | 05/23/1996 | PCT | C12N | 5/00 | | |
| | 96/24356 | 08/15/1996 | PCT | A61K | 31/55 | | |
| | 96/36349 | 11/21/1996 | PCT | A61K | 38/17 | | |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

| **Examiner Initial | |
|-----------------------|---|
| W | "Breast Cancer Prevention Trial Should Resume, ODAC Says", <u>The Breast Cancer Letter</u> , 20 4-5, (1994). |
| I | "Coronary Artery Disease: Restenosis and Reocclusion After Surgical and Nonsurgical Interventions, Part I", <u>Drug & Market Development</u> , 5, 121-129 (1994). |
| | "Nolvadex Tamoxifene Citrate", <u>ICI Pharma</u> , 64033-02, Rev. 1/07/92. |
| | "Prevention of Coronary Heart Disease", In: <u>Avery's Drug Treatment -- Principles and Practice of Clinical Pharmacology and Therapeutics</u> , Speight, T. M., (ed.), Williams and Wilkins, Baltimore, 594-595 (1987). |
| | "Shiga Medical Center for Adult Diseases, "The Impact of Tranilast on Restenosis Following Coronary Angioplasty: The Tranilast Restenosis Following Angioplasty Trial (TREAT)", <u>Circulation</u> , 90, I-82, Abstract No. 0 (1988). |
| ↓ | AinMelk, Y., et al., "Tamoxifen Citrate Therapy in Male Fertility", <u>Fertility and Sterility</u> , 48, 113-117 (1987). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|---|--|
| W | Allemann, et al., "Distribution, Kinetics, and Elimination of Radioactivity after Intravenous and Intramuscular Injection of 14C-Savoxepoine Loaded Poly (D,L-lactic acid) Nanospheres to Rats", <u>J. Controlled Release</u> , <u>29</u> , 97-104 (1994). |
| | Allemann, E., et al., "Drug Loaded Poly(lactic acid) Nanoparticles Produced by a Versible Salting-out Process: Purification of an Injectable Dosage Form", <u>Eur. J. Pharm. Biopharm</u> , <u>39</u> , 13-18 (1993). |
| | Anderson, et al., "Effects of Acetate Dialysate on Transforming Growth Factor B1-interleukin and B2-micorglobulin Plasma Levels", <u>Kidney International</u> , <u>40</u> , 1110-1117 (1991). |
| | Anker, et al., "Plasma Levels of the Atherogenic Amino Acid Homocysteine in Post-Menopausal Women with Breast Cancer Treated with Tamoxifen", <u>Int. J. Cancer</u> , <u>60</u> , 365-368 (1995). |
| | Assoian, et al., "Type Beta Transforming Growth Factor in Human Platelets: Release During Platelet Degranulation and Action on Vascular Smooth Muscle Cells", <u>J. Cell. Biol.</u> , <u>102</u> , 1217-1223 (1986). |
| | Attwood, et al., "A Light Scattering Study on Oil-in-Water Microemulsions", <u>Int'l J. Pharm</u> , <u>52</u> , 165-171 (1989). |
| | Bagdade, J.D., et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition", <u>J. Clinical Endocrinology and Metabolism</u> , <u>70</u> , 1132-1135 (1990). |
| | Barath, et al., "Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury", <u>JACC</u> , <u>13</u> , 252A (1989). |
| | Barinaga, "Gene Therapy for Clogged Arteries Passes to Test in Pigs", <u>Science</u> , <u>265</u> , 738 (1994). |
| | Beck, et al., "Poly(DL-lactide-co-glycolide)/norethisterone microcapsules: an injectible biodegradable contraceptive", <u>Biol. Reprod.</u> , <u>28</u> , 186-195 (1983). |
| | Benita, et al., "Submicron Emulsions as Colloidal Drug Carriers for Intravenous Administration: Comprehensive Physicochemical Characterization", <u>J. of Pharmaceutical Sciences</u> , <u>82</u> , 1069-1079 (1993). |
| ✓ | Bertelli, et al., "Adjuvant Tamoxifen in Primary Breast Cancer: Influence on Plasma Lipids and Antithrombin III Levels", <u>Breast Cancer Res. and Treatment</u> , <u>12</u> , 307-310 (1988). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPBP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|----|--|
| CR | Bier, J.D., et al., "Arterial Remodeling: Importance in Primary Versus Restenotic Lesions", <u>JACC</u> , Abstract No. 875-96, 139A (1994). |
| | Bluming, "Hormone Replacement Therapy: Benefits and Risks for the General Postmenopausal Female Population and for Women with a History of Previously Treated Breast Cancer", <u>Seminars in Oncology</u> , <u>20</u> , 662-674 (1993). |
| | Brott, B.C., et al., "Vessel Remodeling After Angioplasty: Comparative Anatomic Studies", <u>JACC</u> , Abstract No. 875-43, 138A (1994). |
| | Bruengger, et al., "Smooth Muscle Cell of the Canine Prostate in Spontaneous Benign Hyperplasia, Steroid Induced Hyperplasia and Estrogen or Tamoxifen Treated Dogs", <u>J. Urology</u> , <u>130</u> , 1208-1210 (1983). |
| | Bruning, et al., "Tamoxifen, Serum Lipoproteins and Cardiovascular Risk", <u>Br. J. Cancer</u> , <u>58</u> , 497-499 (1988). |
| | Butta, A., et al., "Induction of Transforming Growth Factor Beta1 in Human Breast Cancer in Vivo Following Tamoxifen Treatment", <u>Cancer Research</u> , <u>52</u> , 4261-4164 (1992). |
| | Chander, et al., "Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer", <u>Cancer Res.</u> , <u>51</u> , 5851-5858 (1991). |
| | Chao, et al., "Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from Patients with the Chronic Fatigue Syndrome", <u>Cytokine</u> , <u>3</u> , 292-298 (1991). |
| | Chapman, G.D., et al., "A Bioabsorbable Stent: Initial Experimental Results", <u>Supplement III Circulation</u> , <u>82</u> , Abstract No. 0283, III-72, (1990). |
| | Charlier, et al., "Tamoxifen in the Treatment of Breast Cancer", <u>J. Gynecol. Obstet Biol. Reprod.</u> , <u>23</u> , 751-756 (1994). |
| | Chauhan, A., et al., "Activation of Transforming Growth Factor-beta is Inversely Correlated with Three Major Risk Factors for Coronary Artery Disease: Lipoprotein(a), LDL-Cholesterol and Plasminogen Activator Inhibitor-1", <u>Circulation</u> , <u>90</u> , 67th Scientific Sessions, Abstract No. 3354, I-623 (1994). |
| ✓ | Clowes, A.W., et al., "Kinetics of Cellular Proliferation after Arterial Injury -- I. Smooth Muscle Growth in the Absence of Endothelium", <u>Laboratory Investigation</u> , <u>49</u> , 327-333 (1983). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|----|--|
| CL | Clowes, A.W., et al., "Kinetics of Cellular Proliferation after Arterial Injury -- III. Endothelium and Smooth Muscle Growth in Chronically Denuded Vessels", <u>Laboratory Investigation</u> , <u>54</u> , 295-303 (1986). |
| | Clowes, A.W., et al., "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery", <u>Circulation Research</u> , <u>56</u> , 139-145 (1985). |
| | Cohen, et al., "Controlled Delivery Systems for Proteins Based on Poly(lactic/glycolic acid) Microspheres", <u>Pharmaceutical Research</u> , <u>8</u> , 713-720 (1991). |
| | Colletta, A.A., et al., "Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts", <u>Br. J. Cancer</u> , <u>62</u> , 405-409 (1990). |
| | Coombes, R.C., et al., "Idoxifene: Report of a Phase I Study in Patients with Metastatic Breast Cancer", <u>Cancer Research</u> , <u>55</u> , 1070-1074 (1995). |
| | Cotton, P., "Restenosis Trials Suggest Role for Remodeling", <u>JAMA</u> , <u>271</u> , 1302-1305 (1994). |
| | Cowsar, et al., "Poly(actide-co-glycolide) Microcapsules for Controlled Release of Steroids", <u>Methods Enzymology</u> , <u>112</u> , 101-116 (1985). |
| | Craig, et al., "Anticoagulant Drugs", In Modern Pharmacology, Little, Brown and Co., Boston, 399 (1982). |
| | Currier, J.W., et al., "Restenosis After Percutaneous Transluminal Coronary Angioplasty: Have We Been Aiming at the Wrong Target?", <u>JACC</u> , <u>25</u> , 516-520 (1995). |
| | Danielpour, "Improved Sandwich Enzyme-linked Immunosorbent Assays Transforming Growth Factor B1", <u>J. Immunol. Methods</u> , <u>158</u> , 17-25 (1993). |
| | Danielpour, D., et al., "Evidence for Differential Regulation of TGF-Betal and TGF-Beta2 Expression in Vivo by Sandwich Enzyme-linked Immunosorbent Assays", <u>Annals N.Y. Acad. Sci.</u> , <u>593</u> , 300-302 (1990). |
| | Danielpour, D., et al., "Immunodetection and Quantitation of the Two Forms of Transforming Growth Factor-Beta (TGF-Betal and TGF-Beta2) Secreted by Cells in Culture", <u>J. Cell. Physiol.</u> , <u>138</u> , 79-86 (1989). |
| ✓ | Dasch, J.R., et al., "Capture Immunoassays Specific for TGF-Betal and TGF-Beta2: Use in Pharmacokinetic Studies", <u>Annals N.Y. Acad. Sci.</u> , <u>593</u> , 303-305 (1990). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|---|--|
| W | Davies, A.M., et al., "Peroxidase Activation of Tamoxifen and Toremifene Resulting in DNA Damage and Covalently Bound Protein Adducts", <u>Carcinogenesis</u> , <u>16</u> , 539-545 (1995). |
| | Di Mario, C., et al., "Is the Mechanism of Restenosis Device-Independent? Serial Assessment with Intracoronary Ultrasound", <u>Circulation</u> , <u>90</u> , Abstract No. 115, I-24 (1994). |
| | Dimond, P.F., "TGF-Beta Shows Potential as Therapeutic Agent for Macular Holes", <u>Genetic Engineering News</u> , pages 7, 19 (1993). |
| | Dowsett, M., "New Developments in the Hormonal Treatment of Breast Cancer", In: The Treatment of Cancer: Beyond Chemotherapy, Conference Documentation, The Gloucester Hotel, London, 7 p., (1995). |
| | Dragan, Y.P., et al., "Comparison of the Effects of Tamoxifen and Toremifene on Liver and Kidney Tumor Promotion in Female Rats", <u>Carcinogenesis</u> , <u>16</u> , 2733-2741 (1995). |
| | Ebner, et al., "Cloning of a Type I TGF-B Receptor and Its Effect on TGF-B Binding to the Type II Receptor", <u>Science</u> , <u>260</u> , 1344-1348 (1993). |
| | Edelman, E.R., et al., "Effect of Controlled Adventitial Heparin Delivery on Smooth Muscle Cell Proliferation Following Endothelial Injury", <u>Proc. Natl. Acad. Sci. USA</u> , <u>87</u> , 3773-3777 (1990). |
| | Eldridge, J.H., et al., "Biodegradable and Biocompatible Poly(DL-Lactide-Co-Glycolide) Microspheres as an Adjuvant for Staphylococcal Enterotoxin B Toxoid Which Enhances the Level of Toxin-Neutralizing Antibodies", <u>Infection and Immunity</u> , <u>59</u> , 2978-2986 (1991). |
| | Fanelli, C., et al., "Restenosis Following Coronary Angioplasty", <u>American Heart Journal</u> , <u>119</u> , 357-368 (1990). |
| | Farhat, et al., "In Vitro Effect of Oestradiol on Thymidine Uptake in Pulmonary Vascular Smooth Muscle Cell: Role of the Endothelium.", <u>Br. J. Pharmacol.</u> , <u>107</u> , 679-683 (1992). |
| | Faxon, D.P., et al., "Restenosis Following Transluminal Angioplasty in Experimental Atherosclerosis", <u>Arteriosclerosis</u> , <u>4</u> , 189-195 (1984). |
| ✓ | Fischell, T.A., et al., "Low-Dose, beta-Particle Emission From 'Stent' Wire Results in Complete, Localized Inhibition of Smooth Muscle Cell Proliferation", <u>Circulation</u> , <u>90</u> , 2956-2963 (1994). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPPE 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initials

| | |
|---|--|
| W | Fischer, et al., "A Possible Mechanism in Arterial Wall for Mediation of Sex Difference in Atherosclerosis Experimental and Molecular Pathology", <u>Exp. Mol. Pathol.</u> , <u>43</u> , 288-296 (1985). |
| f | Fischman, D.L., et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease", <u>The New England Journal of Medicine</u> , <u>331</u> , 496-501 (1994). |
| | Forrester, J.S., et al., "A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies", <u>JACC</u> , <u>17</u> , 758-769 (1991). |
| | Frazier-Jessen, et al., "Estrogen Modulation of JE/Monocyte Chemoattractant Protein-1 mRNA Expression in Murine Macrophages", <u>J. Immunol.</u> , <u>154</u> , 1828-1845 (1994). |
| | Friberg, et al., "Microemulsions and Solubilization by Nonionic Surfactants", <u>Prog. Colloid and Polymer Sci.</u> , <u>56</u> , 16-20 (1975). |
| | Furr, B.J., et al., "The Pharmacology and Clinical Uses of Tamoxifen", <u>Pharmac. Ther.</u> , <u>25</u> , 127-205 (1984). |
| | Gasco, et al., "In Vitro Permeation of Azelaic Acid from Viscosized Microemulsions", <u>International Journal of Pharmaceutics</u> , <u>69</u> , 193-196 (1991). |
| | Gasco, M.R., et al., "Long-acting Delivery Systems for Peptides: Reduced Plasma Testosterone Levels in Male Rats after a Single Injection", <u>Intl. J. of Pharmaceut.</u> , <u>62</u> , 119-123 (1990). |
| | Gertz, S.D., et al., "Geometric Remodeling Is Not the Principal Pathogenic Process in Restenosis After Balloon Angioplasty", <u>Circulation</u> , <u>90</u> , 3001-3009 (1994). |
| | Giachelli, et al., "Osteopontin is Elevated During Neointima Formation in Rat Arteries and is a Novel Component of Human Atherosclerosis Plaques", <u>J. Clin. Invest.</u> , <u>92</u> , 1686-1696 (1993). |
| | Gibbons, G.H., et al., "The Emerging Concept of Vascular Remodeling", <u>New England Journal of Medicine</u> , <u>330</u> , 1431-1438 (1994). |
| | Glagov, S., "Intimal Hyperplasia, Vascular Modeling, and the Restenosis Problem", <u>Circulation</u> , <u>89</u> , 2888-2891 (1994). |
| ✓ | Glagov, S., et al., "Compensatory Enlargement of Human Atherosclerotic Coronary Arteries", <u>New England Journal of Medicine</u> , <u>316</u> , 1371-1375 (1987). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|----|---|
| UR | Goldman, et al., "Influence of Pressure on Permeability of Normal and Diseased Muscular Arteries to Horseradish Peroxidase.", <u>Atherosclerosis</u> , <u>65</u> , 215-225 (1987). |
| | Grainger, D.J., et al., "A Large Accumulation of Non-Muscle Myosin Occurs at First Entry into M Phase in Rat Vascular Smooth-Muscle Cells.", <u>Biochemical Journal</u> , <u>277</u> , 145-151 (1991). |
| | Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis?", <u>Biol. Rev.</u> , <u>70</u> , 571-596 (1995). |
| | Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo", <u>Circulation</u> , <u>90</u> , 67th Scientific Session, Abstract No. 3353, I-623 (1994). |
| | Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein(a) Mice", <u>Nature</u> , <u>370</u> , 460-462 (1994). |
| | Grainger, D.J., et al., "Active and Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", <u>Clinica Chemica Acta.</u> , <u>235</u> , 11-31 (1995). |
| | Grainger, D.J., et al., "Active TGF-beta is Depressed Five-Fold in Triple Vessel Disease Patients Compared with Syndrome X Patients", <u>Journal of Cellular Biochemistry</u> , <u>18A</u> , Abstract No. E111, 267 (1994). |
| | Grainger, D.J., et al., "Active Transforming Growth Factor-beta is Depressed in Patients with Three Vessel Coronary Artery Disease", <u>Circulation</u> , <u>90</u> , 67th Scientific Sessions, Abstract No. 2754, I-512 (1994). |
| | Grainger, D.J., et al., "Effect of Tamoxifen in the Rat Carotid Injury Model In Vivo", Manuscript in Preparation, (1996). |
| | Grainger, D.J., et al., "Heparin Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells by Releasing Transforming Growth Factor beta-like Activity from Serum", <u>Cardiovascular Research</u> , <u>27</u> , 2238-2247 (1993). |
| | Grainger, D.J., et al., "Hexamethylenebisacetamide Selectively Inhibits the Proliferation of Human and Rat Vascular Smooth-Muscle Cells", <u>Biochemical Journal</u> , <u>283</u> , 403-408 (1992). |
| | Grainger, D.J., et al., "Mitogens for Adult Rat Aortic Vascular Smooth Muscle Cells in Serum-Free Primary Culture", <u>Cardiovascular Research</u> , <u>28</u> , 1238-1242 (1994). |
| ✓ | Grainger, D.J., et al., "Proliferation of Human Smooth Muscle Cells Promoted by Lipoprotein(a)", <u>Science</u> , <u>260</u> , 1655-1658 (1993). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|----|--|
| CM | Grainger, D.J., et al., "Release and Activation of Platelet Latent TFG-Beta in Blood Clots During Dissolution with Plasmin", <u>Nature Medicine</u> , <u>1</u> , 932-937 (1995). |
| | Grainger, D.J., et al., "Tamoxifen Decreases the Rate of Proliferation of Rat Vascular Smooth-Muscle Cells in Culture by Inducing Production of Transforming Growth Factor Beta", <u>Biochem J.</u> , <u>294</u> , 109-112 (1993). |
| | Grainger, D.J., et al., "Tamoxifen: Teaching an Old Drug New Tricks?", <u>Nature Medicine</u> , <u>2</u> , 381-385 (1996). |
| | Grainger, D.J., et al., "The Serum Concentration of Active Transforming Growth Factor-beta is Severly Depressed in Advanced Atherosclerosis", <u>Nature Medicine</u> , <u>1</u> , 74-80 (1995). |
| | Grainger, D.J., et al., "Transforming Growth Factor beta Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells by Extending the G2 Phase of the Cell Cycle and Delays the Rise in Cyclic AMP Before Entry into M Phase", <u>Biochemical Journal</u> , <u>299</u> , 227-235 (1994). |
| | Grainger, D.J., et al., "Transforming Growth Factor-beta: The Key to Understanding Lipoprotein(a)?", <u>Current Opinion In Lipidology</u> , <u>6</u> , 81-85 (1995). |
| | Gref, et al., "Biodegradable Long-Circulating Polymeric Nanoshpheres.", <u>Science</u> , <u>263</u> , 1600-1603 (1994). |
| | Grey, A.B., et al., "The Effect of the Anti-Estrogen Tamoxifen on Cardiovascular Risk Factors in Normal Postmenopausal Women", <u>J. Clinical Endocrinology and Metabolism</u> , <u>80</u> , 3191-3195 (1995). |
| | Gylling, H., et al., "Tamoxifen and Toremifene Lower Serum Cholesterol by Inhibition of Delta8-Cholesterol Conversion to Lathosterol in Women with Breast Cancer", <u>Journal of Clinical Oncology</u> , <u>13</u> , 2900-2905 (1995). |
| | Hall, I.H., et al., "Hypolipidemic Activity of Tetrakis-mu-(trimethylamine-borane-carboxylato)-bis(trimethylamine-carboxyborane)-dicopper(II) in Rodents and Its Effect on Lipid Metabolism", <u>J. Pharmaceut. Sci.</u> , <u>73</u> , 973-977 (1984). |
| ✓ | Hanke, H., et al., "Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low-Molecular-Weight Heparin", <u>Circulation</u> , <u>85</u> , 1548-1556 (1992). |

Examiner

Chercher

Date Considered

6/2/02

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPSP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|----|---|
| ca | Harpel, et al., "Plasmin Catalysis Binding of Lipoprotein (A) to Immobilized Fibrinogen and Fibrin.", <u>Proc. Natl. Acad. Sci. USA</u> , <u>86</u> , 3847-3851 (1989). |
| | Hehrlein, C., et al., "Low-Dose Radiactive Endovascular Stents Prevent Smooth Muscle Cell Proliferation and Neointimal Hyperplasia in Rabbits", <u>Circulation</u> , <u>92</u> , 1570-1575 (1995). |
| | Hehrlein, C., et al., "Pure Beta-particle-emitting Stents Inhibit Neointima Formation in Rabbits", <u>Circulation</u> , <u>93</u> , 641-645 (1996). |
| | Heldin, et al., "Demonstration of an Antibody Against Platelet-Derived Growth Factor.", <u>Exp. Cell. Res.</u> , <u>136</u> , 255-261 (1981). |
| | Heller, et al., "Preparation of Polyacetals by the Reaction of Divinyl Ethers and Polyols.", <u>J. Polymer Science, Polymer Letters Edition</u> , <u>18</u> , 293-297 (1980). |
| | Henriksson, et al., "Hormonal Regulation of Serum Lp (a) Levels.", <u>J. Clin. Invest.</u> , <u>89</u> , 1166-1171 (1992). |
| | Hofmann, J., et al., "Enhancement of the Antiproliferative Effect of cis-Diamminedichloroplatinum(II) and Nitrogen Mustard by Inhibitors of Protein Kinase C", <u>Int. J. Cancer</u> , <u>42</u> , 382-388 (1988). |
| | Holmes, Jr., D.R., "Remodeling Versus Smooth Muscle Cell Hyperplasia.", <u>Restenosis Summit VI</u> , The Cleveland Clinic Foundation, 222-223 (1994). |
| | Hwang, et al., "Effects of Platelet-Contained Growth Factors (PDGF, EGF, IGF-1, and TGF-B) on DNA Synthesis in Porcine Aortic Smooth Muscle Cells in Culture.", <u>Exp. Cell Res.</u> , <u>200</u> , 358-360 (1992). |
| | Isner, J.M., "Vascular Remodeling: Honey, I Think I Shrunk the Artery", <u>Circulation</u> , <u>89</u> , 2937-2841 (1994). |
| | Johnson, et al., "Coronary Atherectomy: Light Microscopic and Immunochemical Study of Excised Tissues", <u>Supp. II Circulation</u> , <u>78</u> , Abstract No. 0327, 11-82 (1988). |
| | Jordan, et al., "Long-Term Tamoxifen Therapy to Control or to Prevent Breast Cancer: Laboratory Concept to Clinical Trials", <u>Hormones, Cell Biology, and Cancer: Perspectives and Potentials</u> , Alan R. Liss, Inc., 105-123 (1988). |
| ✓ | Kakuta, T., et al., "Differences in Compensatory Vessel Enlargement, Not Intimal Formation, Account for Restenosis After Angioplasty in the Hypercholesterolemic Rabbit Model", <u>Circulation</u> , <u>89</u> , 2809-2815 (1994). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)



**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|--|--|
|  | Kakuta, T., et al., "The Impact of Arterial Remodeling on the Chronic Lumen Size After Angioplasty in the Atherosclerotic Rabbit", <u>JACC</u> , Abstract No. 875-95, 138A (1994). |
| | Kambic, H., et al., "Biomaterials in Artificial Organs", <u>Chemical & Engineering News</u> , 30, 31-48 (1986). |
| | Kemp, P.R., et al., "Inhibition of PDGF BB Stimulated DNA Synthesis in Rat Aortic Vascular Smooth Muscle Cells by the Expression of a Truncated PDGF Receptor", <u>FEBS Letters</u> , 336, 119-123 (1993). |
| | Kemp, P.R., et al., "The Id Gene is Activated by Serum but is Not Required for De-differentiation in Rat Vascular Smooth Muscle Cells", <u>Biochemical Journal</u> , 277, 285-288 (1991). |
| | Kirschenlohr, H.L., et al., "Adult Human Aortic Smooth Muscle Cells in Culture Produce Active TFG-Beta", <u>Amer. J. Physiol</u> , 265, C571-C576 (1993). |
| | Kirschenlohr, H.L., et al., "Proliferation of Human Aortic Vascular Smooth Muscle Cells in Culture is Modulated by Active TGF-Beta", <u>Cardiovascular Research</u> , 29, 848-855 (1995). |
| | Knabbe, C., et al., "Evidence That Transforming Growth Factor beta is a Hormonally Regulated Negative Growth Factor in Human Breast Cancer Cells", <u>Cell</u> , 48, 417-428 (1987). |
| | Knabbe, C., et al., "Induction of Transforming Growth Factor-B by the Antiestrogens Droloxifene, Tamoxifen, and Toremifene in MCF-7 Cells", <u>Am. J. Clin. Oncol.</u> , 14, S15-S20 (1991). |
| | Koff, et al., "Negative Regulation of G1 in Mammalian Cells: Inhibition of Cyclin E-Dependent Kinase by TGF-B.", <u>Science</u> , 260, 536-538 (1993). |
| | Kotoulas, I.G., et al., "Tamoxifen Treatment in Male Infertility. I. Effect on Spermatozoa", <u>Fertility and Sterility</u> , 61, 911-914 (1994). |
| | Kovach, J.A., et al., "Serial Intravascular Ultrasound Studies Indicate that Chronic Recoil is an Important Mechanism of Restenosis Following Transcatheter Therapy", <u>JAAC</u> , 21, Abstract No. 835-3, 484A (1993). |
|  | Koyama, N., et al., "Regulation of Smooth Muscle Cells Migration by a New Autocrine Migration Factor and TGF-beta", <u>Circulation</u> , 84, Abstract No. 1829, II-459 (1991). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|----------|--|
| <i>W</i> | Kreuzer, J., et al., "Lipoprotein(a) Displays Increased Accumulation Compared with Low-Density Lipoprotein in the Murine Arterial Wall", <u>Chemistry and Physics of Lipids</u> , 67/68, 175-190 (1990). |
| | Kuntz, R.E., et al., "Defining Coronary Restenosis -- Newer Clinical and Angiographic Paradigms", <u>Circulation</u> , 88, 1310-1323 (1993). |
| | Kunz, L.L., et al., "Efficacy of Cytochalasin B in Inhibiting Coronary Restenosis Caused by Chronic Remodeling After Balloon Trauma in Swine", <u>Journal of the American College of Cardiology</u> , Supplement A, Abstract No. 984-23, 302 (1995). |
| | Kunz, L.L., et al., "Inhibition of Microfilament Reorganization Following Balloon Angioplasty Decreases Extent of Geometric Remodeling in Restenosis", <u>JACC</u> , 44th Annual Scientific Session, Abstract No. 122292 (1995). |
| | Kunz, L.L., et al., "Sustained Dilation and Inhibition of Restenosis in a Pig Femoral Artery Injury Model", <u>Circulation</u> , 90, 67th Scientific Sessions, Abstract No. 1598, I-297 (1994). |
| | Labhsetwar, V., "Nanoparticles for site specific delivery of U-86983 in restenosis on pig coronary arteries", <u>Proc. Intern. Symp. Control. Rel. Bioact. Mater.</u> , 22, 182-183 (1995). |
| | Lafont, A.M., et al., "Post-Angioplasty Restenosis in the Atherosclerotic Rabbit: Proliferative Response or Chronic Constriction?", <u>Circulation</u> , 88, 66th Scientific Sessions, Abstract No. 2806, I-521 (1993). |
| | Laird, J., et al., "Inhibition of Neointimal Proliferation with Low-dose Irradiation from a Beta-particle-emitting Stent", <u>Circulation</u> , 93, 529-536 (1996). |
| | Lambert, C.R., et al., "Local Drug Delivery Catheters: Functional Comparison of Porous and Microporous Designs", <u>Coronary Artery Disease</u> , 4, 469-475 (1993). |
| | Langbein, W., "Too Many Drugs, Too Little Value in CV Conditions", <u>In Vivo</u> , 14-20 (1995). |
| <i>✓</i> | Lazier, C.B., et al., "Comparison of the Effects of Tamoxifen and of a Tamoxifen Analogue that Does Not Bind the Estrogen Receptor on Serum Lipid Profiles in the Cockerel", <u>Biochem. Cell Biol.</u> , 68, 210-217 (1990). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPBP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|---|--|
| u | Lefer, "Role of Transforming Growth Factor Beta in Cardioprotection of the Ischemic-Reperfused Myocardium", <u>Growth Factors and the Cardiovascular System</u> , P. Cummins, ed., Kluwer Academic Publishers, 249-260 (1993). |
| | Lefer, et al., "Mechanisms of the Cardioprotective Effect of Transforming Growth Factor B1 in Feline Myocardial Ischemia and Reperfusion", <u>PNAS (USA)</u> , 90, 1018-1022 (1993). |
| | Lefer, A.M., et al., "Mediation of Cardioprotection by Transforming Growth Factor Beta", <u>Science</u> , 249, 61-64 (1990). |
| | Lehmann, K., et al., "Effect of cilazapril on the proliferative response after vascular damage", <u>J. of Cardiovascular Pharmacology</u> , 22, S19-24 (1993). |
| | Lehmann-Bruinsma, et al., "Transforming Growth Factor B2(TGF-B) Suppression of Smooth Muscle Cell (SMC) Proliferation After Balloon Angioplasty of Rat Carotid Arteries", <u>Clin. Res.</u> , 42, Abstract No. 4A (1994). |
| | Leroux, et al., "New Approach for the Preparation of Nanoparticles by an Emulsification-Diffusion Method", <u>Eur. J. Pharm. Biopharm</u> , 41, 14-18 (1995). |
| | Leroux, J.C., et al., "Internalization of poly(D L-lactic acid) nanoparticles by isolated human leukocytes and analysis of plasma proteins adsorbed onto the particles", <u>J. Biomed. Mater. Res.</u> , 28, 471-481 (1994). |
| | Levy, M.Y., "Drug Release from Submicronized O/W Emulsion: A New In Vitro Kinetic Evaluation Model", <u>Intl. J. Pharmaceut</u> , 66, 29-37 (1990). |
| | Levy, R.J., et al., "Strategies for Treating Arterial Restenosis using Polymeric Controlled Release Implants", <u>Chemical Abstracts</u> , 121, Abstract No. 263625g, 580 (1994). |
| | Levy, R.J., et al., "Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants", <u>In: Biotechnology and Bioactive Polymers</u> , Proceedings of an American Chemical Society Symposium, Gebelein, C.G., (ed.), Plenum Press, New York, 259-268 (1994). |
| | Li, et al., "Structure and Dynamics of Microemulsions which Mimic the Lipid Phase of Low-Density Lipoproteins", <u>Biochimica et Biophysica Acta</u> , 1042, 42-50 (1990). |
| ✓ | Liaw, et al., "Osteopontin Promotes Vascular Cell Adhesion and Spreading and is Chemotactic for Smooth Muscle Cells in Vitro", <u>Cir. Res.</u> , 74, 214-224 (1992). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|---|--|
| W | Lin, et al., "Expression Cloning of the TGF-B Type II Receptor, a Functional Transmembrane Serine/Threonine Kinase.", <u>Cell</u> , <u>68</u> , 775-785 (1992). |
| | Lincoff, A.M., et al., "Local Drug Delivery for the Prevention of Restenosis", <u>Circulation</u> , <u>90</u> , 2070-2084 (1994). |
| | Linn, et al., "Microemulsion for Intradermal Delivery of Cetyl Alcohol and Octyl Dimethyl Paba", <u>Drug Development and Industrial Pharmacy</u> , <u>16</u> , 899-920 (1990). |
| | Liu, M.D., et al., "Restenosis After Coronary Angioplasty - Potential Biologic Determinants and Role of Intimal Hyperplasia", <u>Circulation</u> , <u>79</u> , 1374-87 (1989). |
| | Lopez-Casillas, et al., "Beta-glycan Presents Ligand to the TGF-beta Signaling Receptor", <u>Cell</u> , <u>73</u> , 1435-1444 (1993). |
| | Love, et al., "Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women.", <u>Annals of Internal Medicine</u> , <u>115</u> , 860-864 (1991). |
| | Love, et al., "Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients with Node-Negative Breast Cancer", <u>J. Natl. Cancer Ins.</u> , <u>82</u> , 1327-1332 (1990). |
| | Luo, H., et al., "Chronic Vessel Constriction is an Important Mechanism of Restenosis After Balloon Angioplasty: An Intravascular Ultrasound Analysis", <u>Circulation</u> , <u>90</u> , 67 Scientific Sessions, Abstract No. 0318, I-61 (1994). |
| | Macander, et al., "Balloon Angioplasty for Treatment of In-Stent Restenosis: Feasibility, Safety, and Efficacy", <u>Catheterization and Cardiovascular Diagnosis</u> , <u>37</u> , 125-131 (1990). |
| | Magarian, "The Medicinal Chemistry of Nonsteroidal Antiestrogens: A Review", <u>Current Medicinal Chemistry</u> , <u>1</u> , 61-104 (1994). |
| | Majack, R.A., et al., "Role of PDGF-A Expression in the Control of Vascular Smooth Muscle Cell Growth by Transforming Growth Factor-B", <u>The Journal of Cell Biology</u> , <u>111</u> , 239-247 (1990). |
| | Majesky, M.W., et al., "Production of Transforming Growth Factor beta1 During Repair of Arterial Injury", <u>J. Clin. Invest.</u> , <u>88</u> , 904-910 (1991). |
| ✓ | Malcolmson, et al., "A Comparison Between Nonionic Micelles and Microemulsions as a Means of Incorporating the Poorly Water Soluble Drug Diazepam", <u>J. Pharm. Pharmacol.</u> , <u>42</u> , 6P (1990). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|---|---|
| ✓ | Marx, "CMV-p.53 Interaction May Help Explain Clogged Arteries", <u>Science</u> , <u>265</u> , 320 (1994). |
| | Marzocchi, A., et al., "Restenosis After Coronary Angioplasty: Its Pathogenesis and Prevention", <u>Cardiologia</u> , <u>36</u> , Translation, 309-320 (1991). |
| | Massague, "The transforming growth factor-B family", <u>Ann. Rev. Cell Biol.</u> , <u>6</u> , 597-641 (1990). |
| | McCaffrey, T.A., et al., "Fucoidan is a Non-Anticoagulant Inhibitor of Intimal Hyperplasia", <u>Biochemical and Biophysical Research Communications</u> , <u>184</u> , 773-781 (1992). |
| | McCaffrey, T.A., et al., "Transforming Growth Factor-beta Activity is Potentiated by Heparin via Dissociation of the Transforming Growth Factor-beta/alpha2-Macroglobulin Inactive Complex", <u>The Journal of Cell Biology</u> , <u>109</u> , 441-448 (1989). |
| | Mccague, et al., "An Efficient, Large Scale Synthesis of Idoxifene ((E)-1(4-(2-(N-pyrrolidino)ethoxy)-1-(4-iodophenyl)-2-phenyl-1-butene)", <u>Organic Preparations and Proc. Int.</u> , <u>26</u> , 343-346 (1994). |
| | Mccague, et al., "Synthesis of 4-Stannylated Tamoxifen Analogues: Useful Precursors to Radiolabelled Idoxifené and Axiridinyl 4-Iodotamoxifen.", <u>J. Labelled Compounds and Pharmaceuticals</u> , <u>34</u> , 297-302 (1994). |
| | McCaroll, et al., "Preliminary Studies on the Regulation of Secretion of Latent Transforming Growth Factor-B (TGF-B) by Endothelial Cells in Culture.", <u>Clin. Chem.</u> , <u>36</u> , Abstract No. 0934, 1152 (1990). |
| | McClellan, et al., "cDNA sequence of human apolipoprotein (a) is homologous to plasminogen", <u>Nature</u> , <u>330</u> 132-137 (1987). |
| | McCormick, et al., "Retinoid-Tamoxifen Interaction in Mammary Cancer Chemoprevention", <u>Carcinogenesis</u> , <u>7</u> , 193-196 (1986). |
| | McDonald, et al., "Fatal Myocardial Infarction in the Scottish Adjuvant Tamoxifen Trial.", <u>B. Med. J.</u> , <u>303</u> , 435-437 (1991). |
| | McQuiggan, J.D., "Tissue Distribution of Cytochalasin B After Intraperitoneal Bolus and Microencapsulated Injection in Mice and its Effect on beta-N-Acetylglucosaminidase Activity in Cultured B16-BL6 Melanoma Cells", Masters' Thesis, Syracuse University, New York, 41 p., (1988). |
| ✓ | Merrilees, et al., "Synthesis of TGF-B1 by Vascular Endothelial Cells is Correlated with Cell Spreading.", <u>J. Vasc. Res.</u> , <u>29</u> , 376-384 (1992). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|----|--|
| ck | Metcalfe, J.C., et al., "Protein Markers of Lesion Development in the Vessels of Transgenic Apo(a) Mice", <u>Journal of Cellular Biochemistry, Supplement 18A</u> , Abstract No. E212, 280 (1994). |
| | Metcalfe, J.C., et al., "Transforming Growth Factor-beta and the Protection From Cardiovascular Injury Hypothesis", <u>Biochemical Society Transactions</u> , <u>23</u> , 403-406 (1995). |
| | Mintz, G.S., et al., "Chronic Compensatory Arterial Dilation Following Coronary Angioplasty: An Intravascular Ultrasound Study", <u>JACC</u> , Abstract No. 875-97, 138A (1994). |
| | Mintz, G.S., et al., "Geometric Remodeling is the Predominant Mechanism of Clinical Restenosis After Coronary Angioplasty", <u>JACC</u> , Abstract No. 875-42, 138A (1994). |
| | Mintz, G.S., et al., "Mechanisms of Late Arterial Response to Transcatheter Therapy: A Serial Quantitative Angiographic and Intravascular Ultrasound Study", <u>Circulation</u> , <u>90</u> , Abstract No. 117, I-24 (1994). |
| | More, R.S., et al., "A Targeted Antithrombotic Conjugate with Antiplatelet and Fibrinolytic Properties which Reduces in vivo Thrombus Formation", <u>Cardiovascular Research</u> , <u>27</u> , 2200-2204 (1993). |
| | Morisaki, et al., "Effects of transforming growth factor-B, on growth of aortic smooth muscle cells", <u>Atherosclerosis</u> , <u>88</u> , 227-234 (1991). |
| | Mosedale, D.E., et al., "Transforming Growth Factor-beta is Correlated with Smooth Muscle Cell Differentiation in Vivo", <u>Circulation</u> , <u>90</u> , 67th Scientific Session, Abstract No. 1590, I-296 (1994). |
| | Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta 1 Group Into Arteries Stimulates Fibrocellular Hyperplasia", <u>Proc. Natl. Acad. Sci. USA</u> , <u>90</u> , 10759-10763 (1993). |
| | Nakagawa, et al., "A Case of Acute Myocardial Infarction Intracoronary Arteries Due To Hormone Therapy.", <u>Angiology</u> , <u>45</u> , 333-338 (1994). |
| | Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", <u>USB Securities, Equity Research -- Medical Technology</u> , 10 p. (1995). |
| | Nikol, S., et al., "Expression of Transforming Growth Factor Beta 1 is Increased in Human Vascular Restenosis Lesions", <u>J. Clin. Invest.</u> , <u>90</u> , 1582-1592 (1992). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|----|--|
| CL | Nunes, G.L., et al., "Vitamins C and E Improve the Response to Coronary Balloon Injury in the Pig: Effect of Vascular Remodeling", <u>Circulation</u> , 88 , Abstract No. 1994, I-372 (1993). |
| | O'Brien, et al., "Osteopontin mRNA and Protein are Overexposed in Human Coronary Atherectomy Specimens: Clues to Lesion Calcification.", <u>Circulation</u> , 88 , Abstract No. 3330, I-609 (1993). |
| | O'Connor-McCourt, et al., "Latent Transforming Growth Factor-B in Serum: A Specific Complex with α 2-macroglobin", <u>J. Biol. Chem.</u> , 262 , 14090-14099 (1987). |
| | Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Arterial Injury", <u>Science</u> , 265 , 781-784 (1994). |
| | Osborne, et al., "Microemulsions as Topical Drug Delivery Vehicles: In Vitro Transdermal Studies of a Model Hydrophilic Drug", <u>J. Pharm. Pharmacol.</u> , 43 , 451-454 (1991). |
| | Osipow, "Transparent Emulsion", <u>J. Soc. Cosmetic Chemists</u> , 277-285 (1963). |
| | Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertrophy in Cultured Vascular Smooth Muscle Cells", <u>The Journal of Cell Biology</u> , 107 , 771-780 (1988). |
| | Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis", <u>Biochem Mol. Biol. Intern.</u> , 35 , 117-124 (1995). |
| | Palmaz, J.C., et al., "Intravascular Stents", <u>In: Advances in Vascular Surgery</u> , Vol. 1, Mosby-Year Book Inc., 107-135 (1993). |
| | Parthasatathy, S., et al., "A Role for Endothelial Cell Lipoxygenase in the Oxidative Modification of Low Density Lipoprotein", <u>Proc. Nat'l Acad. Sci., USA</u> , 86 , 1046-1050 (1989). |
| | Pathak, et al., "Enhanced Stability of Physostigmine Salicylate in Submicron o/w Emulsion", <u>International Journal of Pharmaceutics</u> , 65 , 169-175 (1990). |
| | Perez, J.R., et al., "Regulation of Adhesion and Growth of Fibrosarcoma Cells by NF-kb RelA Involves Transforming Growth Factor Beta", <u>Molecular and Cellular Biology</u> , 14 , 5326-5332 (1994). |
| | Podzimek, et al., "O/W Microemulsions", <u>J. Dispersion Science and Technology</u> , 1 , 341-359 (1980). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PPEP 1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|----|---|
| cl | Popma, J.J., et al., "Factors Influencing Restenosis after Coronary Angioplasty", <u>The American Journal of Medicine</u> , <u>88</u> , 1-16N--1-24N (1990). |
| | Post, M.J., et al., "Restenosis is Partly Due to Intimal Hyperplasia and Partly to Remodeling of the Injured Arterial Wall", <u>European Heart Journal</u> , Abstract No. P1164, 201 (1993). |
| | Post, M.J., et al., "The Relative Importance of Arterial Remodeling Compared with Intimal Hyperplasia in Lumen Renarrowing After Balloon Angioplasty", <u>Circulation</u> , <u>89</u> , 2816-2821 (1994). |
| | Post, M.J., et al., "Which Part of the Angiographic Diameter Reduction After Balloon Dilation is Due to Intimal Hyperplasia?", <u>JACC</u> , <u>21</u> , Abstract No. 851-95, I-36A (1993). |
| | Potter, et al., "A Mechanism Hypothesis for DNA Adduct Formation Following Hepatic Oxidative Metabolism.", <u>Carcinogenesis</u> , <u>15</u> , 439-442 (1994). |
| | Pouton, C.W., "Self-Emulsifying Drug Delivery Systems: Assessment of the Efficiency of Emulsification", <u>International Journal of Pharmaceutics</u> , <u>27</u> , 335-348 (1985). |
| | Raloff, "Tamoxifen Puts Cancer on Starvation Diet", <u>Science News</u> , <u>146</u> , 292 (1994). |
| | Rauterberg, J., et al., "Collagens in Atherosclerotic Vessel Wall Lesions", <u>Current Topics in Pathology</u> , <u>87</u> , 163-192 (1993). |
| | Reid, V.C., et al., "Fragmentation of DNA in P388D, Macrophages Exposed to Oxidized Low-Density Lipoprotein", <u>FEBS Letters</u> , <u>332</u> , 218-220 (1993). |
| | Reiner, Z., et al., "Antiestrogen Tamoxifen Reduces Lipoprotein(a)", Abstracts, The Second International Conference on Lipoprotein (a), New Orleans, LA, 124 (1992). |
| | Riessen, R., et al., "Prospects for Site-Specific Delivery of Pharmacologic and Molecular Therapies", <u>Journal of the American College of Cardiology</u> , <u>23</u> , 1234-1244 (1994). |
| ✓ | Ross, R., "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s", <u>Nature</u> , <u>362</u> , 801-809 (1993). |
| | Ross, R., et al., "Chronic Inflammation, PGF, TGFbeta, and Smooth Muscle Proliferation", <u>J. Cell. Biochem.</u> , <u>S15C</u> , Abstract No. H006, 142 (1991). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)



**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|---|---|
|  | Ross, R., et al., "Chronic Inflammation, PDGF, TFTB, and Smooth Muscle Proliferation", <u>Molecular Mechanisms of Vascular Diseases</u> , Abstract No. G006, 96 (1991). |
| | Rutsch, W., et al., "Benestent-II Pilot Study: 6 Months Follow Up of Phase 1", <u>Abstract, Society of Cardiology</u> , (1995). |
| | Sagitani, et al., "Microemulsion Systems with a Nonionic Cosurfant", <u>J. Dispersion Science and Technology</u> , 1(2), 151-164 (1980). |
| | Sanders, et al., "Controlled Release of a Lutenizing Hormone-Releasing Hormone Analogue from Poly(d,l-lactide-co-glycolide) Microspheres.", <u>J. Pharmaceutical Science</u> , 73, 1294-1297 (1984). |
| | Sanderson, J.A., et al., "Antibody-Coated Microspheres for Drug Delivery to Prevent Restenosis", <u>Circulation</u> , 90, Abstract No. 2734, I-508 (1994). |
| | Schatz, R.A., et al., "A View of Vascular Stents", <u>Circulation</u> , 79, 445-457 (1989). |
| | Schneiderman, et al., "Increased Type 1 Plasminogen Activator Inhibitor Gene Expression in Atherosclerotic Human Arteries.", <u>PNAS (USA)</u> , 89, 6998-7002 (1992). |
| | Schoenemanne, et al., "The Differential Diagnoses of Spontaneous Pneumothorax and Pulmonary Lymphangiomyomatosis Clinical Picture Diagnoses and Theory.", <u>Chirag</u> , 61, 301-303 (1990); reported in <u>Biosis</u> , 90, 432367 (1990). English abstract only. |
| | Schwartz, R.S., et al., "Restenosis After Balloon Angioplasty -- A Practical Proliferative Model in Porcine Coronary Arteries", <u>Circulation</u> , 82, 2190-2200 (1990). |
| | Schwartz, R.S., et al., "The Restenosis Paradigm Revisted: An Alternative Proposal for Cellular Mechanisms", <u>JACC</u> , 20, 1284-1293 (1992). |
| | Sedlacek, S., "Estrogenic Properties of Tamoxifen on Serum Lipids in Postmenopausal Women with Breast Cancer (BCA)", <u>Breast Cancer Research and Treatment</u> , 14, Abstract No. 82, 153 (1989). |
|  | Serruys, P.W., et al., "A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease", <u>The New England Journal of Medicine</u> , 331, 489-495 (1994). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1443)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPBP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|----|--|
| cl | Serruys, P.W., et al., "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries -- Early Outcome of the Benestent-II Pilot Study", <u>Circulation</u> , <u>93</u> , 412-422 (1996). |
| | Shanahan, C.M., et al., "High Expression of Genes for Calcification-regulating Proteins in Human Atherosclerotic Plaques", <u>Journal of Clinical Investigation</u> , <u>93</u> , 2393-2402 (1994). |
| | Shanahan, C.M., et al., "Isolation of Gene Markers of Differentiated and Proliferating Vascular Smooth Muscle Cells", <u>Circulation Research</u> , <u>73</u> , 193-204 (1993). |
| | Shewmon, et al., "Tamoxifen and Estrogen Lower Circulating Lipoprotein(a) Concentrations in Healthy Postmenopausal Women", <u>Arteriosclerosis and Thrombosis</u> , <u>14</u> , 1589-1593 (1994). |
| | Shewmon, et al., "Tamoxifen Decreases Lipoprotein (a) in Patients with Breast Cancer.", <u>Metabolism</u> , <u>43</u> , 531-532 (1994). |
| | Shewmon, D.A., et al., "Tamoxifen Lowers Lp(a) in Males with Heart Disease", <u>Supplement I Circulation</u> , <u>86</u> , 1345 (1992). |
| | Shoji, et al., "Enhancement of Anti-Inflammatory Effects of Biphenyllylactic Acid by its Incorporation into Lipid Microspheres.", <u>J. Pharm. Pharmacol</u> , <u>38</u> , 118-121 (1986). |
| | Siebenlist, U., et al., "Structure, Regulation and Function of NF-kB", <u>Annu. Rev. Cell. Biol.</u> , <u>10</u> , 405-455 (1994). |
| | Singh, et al., "Phylogenetic Analysis of Platelet-derived Growth Factor by Radio-Receptor Assay.", <u>J. Cell Biol.</u> , <u>95</u> , 667-671 (1982). |
| | Sismondi, et al., "Metabolic Effects of Tamoxifen in Postmenopause.", <u>Anticancer Res.</u> , <u>14</u> , 2237-2244 (1994). |
| | Snow, A.D., et al., "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells", <u>American Journal of Pathology</u> , <u>137</u> , 313-330 (1990). |
| | Song, C., "Dexamethasine-nanoparticles for intra-arterial localization in restenosis in rats", <u>Proceec. Intern. Symp. Control. Rel. Mater</u> , <u>22</u> , 444-445 (1995). |
| | Speir, et al., "Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis", <u>Science</u> , <u>265</u> , 391-394 (1994). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPSP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|----|---|
| 12 | Steele, P.M., et al., "Balloon Angioplasty -- Nature History of the Pathophysiological Response to Injury in a Pig Model", <u>Circulation Research</u> , <u>57</u> , 105-112 (1985). |
| | Stouffer, et al., "TGF beta Has a Biphasic, Concentration Dependent Effect on EFG and PDGR-BB Induced Smooth Muscle Cell Proliferation, Inflammation, Growth Regulatory Molecules and Atherosclerosis.", <u>J. Cellular Biochem, Supplement</u> <u>18A</u> , Abstract No. A321, 288 (1994). |
| | Streuli, C.H., et al., "Extracellular Matrix Regulates Expression of the TGF-Beta 1 Gene", <u>J. Cell Biol.</u> , <u>120</u> , 253-260 (1993). |
| | Suckling, K.E., "Atherosclerosis Patents: Clues to the Next Drug Generation", <u>Bio/Technology</u> , <u>12</u> , 1379-1380 (1994). |
| | Suckling, K.E., "Emerging Strategies for the Treatment of Atherosclerosis as Seen from the Patent Literature", <u>Biochemical Society Transactions</u> , <u>21</u> , 660-662 (1993). |
| | Tanaka, et al., "Prominent Inhibitory Effects of Tranilast on Migration and Proliferation of and Collagen Synthesis by Vascular Smooth Muscle Cells.", <u>Atherosclerosis</u> , <u>107</u> , 179-185 (1994). |
| | Tice, et al., "Biodegradable controlled-release parental systems", <u>Pharmaceutical Technology</u> , 26-35 (1984). |
| | Topol, E.J., et al., "The Restenosis "Antitheory"", <u>Mayo Clin. Proc.</u> , <u>68</u> , 88-90 (1993). |
| | Vanhoutte, "Hypercholesterolaemia, Atherosclerosis and Release of Endothelium-Derived Relaxing Factor by Aggregating Platelets", <u>Eur. Heart J.</u> , <u>12</u> , Suppl. E, 25-32 (1991). |
| | Vargas, et al., "Oestradiol Inhibits Smooth Muscle Cell Proliferation of Pig Coronary Artery.", <u>Br. J. Pharmacol.</u> , <u>109</u> , 612-617 (1993). |
| | Wakefield, et al., "Latent Transforming Growth Factor-B from Human Platelets: A High Molecular Weight Complex Containing Precursor Sequences.", <u>J. Biol. Chem.</u> , <u>263</u> , 7646-7654 (1988). |
| | Wakefield, et al., "Recombinant Latent Transforming Growth Factor-B, has a Longer Plasma Half-Life in Rats than Active Transforming Growth Factor-B, and a Different Tissue Distribution.", <u>J. Clin. Invest.</u> , <u>86</u> , 1976-1984 (1990). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (FD-349)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| |
|---|
| Waksman, R., et al., "Intracoronary Radiation Before Stent Implantation Inhibits Neointima Formation in Stented Porcine Coronary Arteries", <u>Circulation</u> , <u>92</u> , 1383-1386 (1995). |
| Watson, et al., "TGF-B1 and 25-Hydroxcholesterol Stimulate Osteoblast-Like Vascular Cells to Calcify", <u>J. Clin. Invest.</u> , <u>93</u> , 2106-2113 (1994). |
| Weissberg, P.L., et al., "Approaches to the Development of Selective Inhibitors of Vascular Smooth Muscle Cell Proliferation", <u>Cardiovascular Research</u> , <u>27</u> , 1191-1198 (1993). |
| Weissberg, P.L., et al., "Effects of TGF-Beta on Vascular Smooth Muscle Cell Growth", In: <u>Growth Factors and the Cardiovascular System</u> , Cummins, P., (ed.), Kluwer Academic Publishers, 189-205 (1993). |
| Weissberg, P.L., et al., "Is Vascular Smooth Muscle Cell Proliferation Beneficial?", <u>Lancet</u> , <u>347</u> , 305-307 (1996). |
| Weissberg, P.L., et al., "The Endothelin Peptides ET-1, ET-2, ET-3 and Sarafotoxin S6b are Co-mitogenic with Platelet-Derived Growth Factor for Vascular Smooth Muscle Cells", <u>Atherosclerosis</u> , <u>85</u> , 257-262 (1990). |
| Wight, T.N., "The Extracellular Matrix and Atherosclerosis", <u>Current Opinion in Lipidology</u> , <u>6</u> , 326-334 (1995). |
| Wilensky, R.L., et al., "Direct Intraarterial Wall Injection of Microparticles via a Catheter: A Potential Drug Delivery Strategy Following Angioplasty", <u>American Heart Journal</u> , <u>122</u> , 1136-1140 (1991). |
| Winslow, R., "Going for the Flow", <u>The Wall Street Journal</u> , (1995). |
| Wiseman, H., "Tamoxifen as an Antioxidant and Cardioprotectant", <u>Biochem. Soc. Symp.</u> , <u>61</u> , 209-219 (1995). |
| Wolf, Y.G., et al., "Antibodies Against Transforming Growth Factor Beta1 Suppress Intimal Hyperplasia in a Rat Model", <u>J. Clin. Invest.</u> , <u>93</u> , 1172-1178 (1994). |
| Wolinsky, H., et al., "Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin Into the Wall of the Normal Canine Artery.", <u>JACC</u> , <u>15</u> , 475-481 (1990). |
| Wrana, et al., "Mechanism of Activation of the TGF-B Receptor", <u>Nature</u> , <u>370</u> , 341-347 (1994). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| | |
|---|---|
| W | Yang, N.N., et al., "Estrogen Receptor: One Transcription Factor, Two Genomic Pathways", <u>Calcified Tissue Intl.</u> , <u>54</u> , 342 (1994). |
| I | Young, H., et al., "Pharmacokinetics and Biodistribution of Radiolabelled Idoxifene: Prospects for the Use of PET in the Evaluation of a Novel Antioestrogen for Cancer Therapy", <u>Nucl. Med. Biol.</u> , <u>22</u> , 405-411 (1995). |
| | Zuckerman, et al., "Cytokine Regulation of Macrophage apo E. Secretion: Opposing Effects of GM-CSF and TGF-B.", <u>Atherosclerosis</u> , <u>96</u> , 203-214 (1992). |
| V | Zuckerman, et al., "Exogenous Glucocorticoids Increase Macrophage Secretion of apo E by Cholesterol Independent Pathways.", <u>Atherosclerosis</u> , <u>103</u> , 43-54 (1993). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

| US PATENT DOCUMENTS | | | | | | |
|---------------------|---------------------|------------------|---|-------|----------|----------------------------|
| Examiner Initial* | USP Document Number | Publication Date | Name of Patentee or Applicant of cited Document | Class | Subclass | Filing Date If Appropriate |
| J | 5,411,988 | 05/02/1995 | Bockow et al. | 514 | 560 | 10/27/1993 |
| | 5,445,941 | 08/29/1995 | Yang | 435 | 6 | 06/21/1993 |
| | 5,446,070 | 08/29/1995 | Mantelle | 514 | 772.6 | 08/27/1993 |
| | 5,496,851 | 03/05/1996 | Grinnell | 514 | 443 | 04/14/1995 |
| | 5,605,700 | 02/25/1997 | DeGregorio et al. | 424 | 448 | 10/31/1994 |
| | 5,652,259 | 07/29/1997 | May | 514 | 422 | 05/09/1996 |
| | 6,410,587 | 06/25/2002 | Grainger et al. | 514 | 445 | 05/05/2000 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|---------------------|------------------|---|-------|----------|----------------|
| Examiner Initials* | Foreign Document No | Publication Date | Name of Patentee or Applicant of cited Document | Class | Subclass | T ² |
| J | EP 0 377 526 | 07/11/1990 | Abdel-Monem et al. | C07F | 1/08 | |
| | EP 0 675 103 | 10/04/1995 | Horrobin et al. | C07C | 69/612 | |
| | EP 0 684 259 | 11/29/1995 | Koyama et al. | C07K | 5/09 | |
| | WO 96/21442 | 07/18/1996 | Korsaard et al. | A61K | 31/40 | |

| OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|----------------------|---|----------------|
| Examiner Initials* | Cite No ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| J | | "Schering/Orion Fareston Anti-Estrogen for Treatment of Metastatic Breast Cancer 'Similar' to Tamoxifen, FDA Oncologic Committee Says in Approval Vote", F-D-C Reports, 15-16 (1995). | |
| | | HARDCASTLE et al., "Homologs of Idoxifene: Variation of Estrogen Receptor Binding and Calmodulin Antagonism with Chain Length", J. Med. Chem., 39, 999-1004 (1996). | |
| | | HAYES et al., "Randomized Comparison of Tamoxifen and Two Separate Doses of Toremifene in Postmenopausal Patients with Metastatic Breast Cancer", Journal of Clinical Oncology, 13, 2556-2566 (1995). | |
| | | JONES et al., "Increased Susceptibility to Metal Catalysed Oxidation of Diabetic Lens β_L Crystallin: Possible Protection by Dietary Supplementation with Acetylsalicylic Acid", Exp. Eye Res., 57, 783-790 (1993). | |
| | | LOSER et al., "In Vivo and in Vitro Antiestrogenic Action of 3-Hydroxytamoxifen, Tamoxifen and 4-Hydroxytamoxifen", Eur. J. Cancer Clin. Oncol., 21, 985-990 (1985). | |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

| OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|----------------------|---|----------------|
| Examiner Initials* | Cite No ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| <i>ln</i> | | MOORTHY et al., "Tamoxifen Metabolic Activation: Comparison of DNA Adducts Formed by Microsomal and Chemical Activation of Tamoxifen and 4-Hydroxytamoxifen with DNA Adducts Formed in Vivo", <u>Cancer Research</u> , <u>56</u> , 53-57 (1996). | |
| <i>ln</i> | | MURPHY et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation <i>In Vitro</i> ", <u>Endocrinology</u> , <u>116</u> , 1071-1078 (1985). | |
| <i>ln</i> | | MURPHY et al., "Structure-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: Importance of Hydroxyl Group and Side Chain Positioning for Biological Activity", <u>Molecular Pharmacology</u> , <u>39</u> , 421-428 (1991). | |
| <i>ln</i> | | SARGENT et al., "Induction of Hepatic Aneuploidy <i>In Vivo</i> by Tamoxifen, Toremifene and Idoxifene In Female Sprague-Dawley Rats", <u>Carcinogenesis</u> , <u>17</u> , 1051-1056 (1996). | |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*

Atty. Docket No.: 295.009US4

Serial No. Unknown

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant: David J. Grainger et al.

Filing Date: Herewith

Group: Unknown

US PATENT DOCUMENTS

| Examiner Initial * | Document Number | Date | Name of Patentee or Applicant of Document | Class | Subclass | Filing Date |
|--------------------|-----------------|------------|---|-------|----------|-------------|
| W | 4,282,246 | 08/04/1981 | Holland | 424 | 275 | 03/07/1980 |
| | 4,287,190 | 09/01/1981 | Boettcher et al. | 424 | 230 | 11/29/1979 |
| | 4,310,523 | 01/12/1982 | Neumann | 424 | 240 | 10/10/1980 |
| | 4,317,915 | 03/02/1982 | Confalone et al. | 549 | 68 | 01/14/1980 |
| | 4,382,143 | 05/03/1983 | Shepherd | 549 | 68 | 07/23/1979 |
| | 4,428,963 | 01/31/1984 | Confalone et al. | 424 | 275 | 03/10/1983 |
| | 4,440,754 | 04/03/1984 | Sorenson | 424 | 140 | 05/23/1980 |
| | 4,629,694 | 12/16/1986 | Harpel | 435 | 7 | 07/12/1983 |
| | 4,758,555 | 07/19/1988 | Sorenson | 514 | 186 | 12/08/1986 |
| | 4,767,758 | 08/30/1988 | Breccia et al. | 514 | 231.5 | 02/26/1987 |
| | 4,952,607 | 08/28/1990 | Sorenson | 514 | 589 | 01/30/1986 |
| | 4,999,347 | 03/12/1991 | Sorenson | 514 | 159 | 10/20/1989 |
| | 5,082,834 | 01/21/1992 | Sorenson | 514 | 159 | 09/18/1990 |
| | 5,118,791 | 06/02/1992 | Burnier et al. | 530 | 326 | 06/13/1991 |
| | 5,280,040 | 01/18/1994 | Labroo et al. | 514 | 422 | 03/11/1993 |
| | 5,332,576 | 07/26/1994 | Mantelle | 424 | 443 | 05/21/1993 |
| | 5,420,243 | 05/30/1995 | Ogawa et al. | 530 | 324 | 01/26/1993 |
| | 5,451,603 | 09/19/1995 | Piggott | 514 | 422 | 03/11/1993 |
| | 5,453,492 | 09/26/1995 | Bützow et al. | 530 | 413 | 07/28/1993 |
| | 5,480,903 | 01/02/1996 | Piggott | 514 | 422 | 04/17/1994 |
| | 5,482,851 | 01/09/1996 | Derynck et al. | 435 | 240.1 | 11/05/1993 |
| | 5,484,797 | 01/16/1996 | Bryant et al. | 514 | 319 | 04/21/1995 |
| | 5,521,172 | 05/28/1996 | Bryant et al. | 514 | 212 | 08/15/1995 |
| | 5,552,433 | 09/03/1996 | Bryant et al. | 514 | 443 | 08/15/1995 |
| | 5,556,876 | 09/17/1996 | Bryant et al. | 514 | 443 | 08/15/1995 |
| | 5,610,168 | 03/11/1997 | Draper | 514 | 333 | 04/14/1995 |
| | 5,641,790 | 06/24/1997 | Draper | 514 | 333 | 04/14/1995 |
| | 5,658,883 | 08/19/1997 | Ogawa et al. | 514 | 12 | 03/08/1995 |
| | 5,658,951 | 08/19/1997 | Magarian et al. | 514 | 596 | 06/07/1995 |
| | 5,686,476 | 11/11/1997 | May | 514 | 324 | 03/15/1995 |
| | 5,688,813 | 11/18/1997 | Sall et al. | 514 | 324 | 04/14/1995 |
| | 5,747,510 | 05/05/1998 | Draper | 514 | 333 | 01/27/1997 |
| | 5,773,479 | 06/30/1998 | Grainger et al. | 514 | 651 | 11/21/1995 |
| | 5,824,647 | 10/20/1998 | Postlethwaite et al. | 514 | 13 | 06/01/1995 |
| | 6,166,090 | 12/26/2000 | Grainger et al. | 514 | 651 | 11/06/1997 |
| | 6,197,789 | 03/06/2001 | Grainger et al. | 514 | 319 | 06/07/1996 |
| | 6,251,920 | 06/26/2001 | Grainger et al. | 514 | 319 | 05/21/1998 |
| | 6,262,079 | 07/17/2001 | Grainger et al. | 514 | 319 | 05/06/1999 |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449*

Atty. Docket No.: 295.009US4

Serial No. Unknown

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant: David J. Grainger et al.

Filing Date: Herewith

Group: Unknown

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Foreign Document No | Publication Date | | Class | Subclass | T* |
|--------------------|---------------------|------------------|--|-------|----------|----------|
| W | EP 0 002 341 | 06/13/1979 | | C07C | 65/10 | |
| | EP 0 024 096 | 02/25/1981 | | C07F | 1/08 | |
| | EP 0 302 034 | 02/01/1989 | | C08B | 37/10 | |
| | EP 0 659 418 | 06/28/1995 | | A61K | 31/445 | |
| | JP 9255570 | 03/21/1996 | | A61K | 31/35 | Abstract |
| | JP 6025288 | 02/01/1994 | | | | Abstract |
| | JP 59042375 | 03/08/1984 | | C07D | 333/32 | Abstract |
| | GB 1,587,084 | 03/25/1981 | | | | |
| | WO 85/00107 | 01/17/1985 | | A61K | 31/13 | Full |
| | WO 94/20098 | 09/15/1994 | | A61K | 31/40 | |
| | WO 94/20099 | 09/15/1994 | | A61K | 31/40 | |
| | WO 94/26303 | 11/24/1994 | | A61K | 39/00 | |
| | WO 94/26888 | 11/24/1994 | | C12N | 15/11 | |
| | WO 94/28721 | 12/22/1994 | | A01N | 43/42 | |
| | WO 95/05191 | 02/23/1995 | | A61K | 38/00 | |
| | WO 95/17095 | 06/29/1995 | | A01N | 43/38 | |
| | WO 96/07402 | 03/14/1996 | | A61K | 31/075 | |
| | WO 96/21443 | 07/18/1996 | | A61K | 31/40 | |
| | WO 96/40098 | 12/19/1996 | | A61K | 31/135 | |

| Examiner Initials* | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
|--------------------|---|
| W | "Health Report -- The Good News", Time, 23 (1996). |
| | "Heparin", In: Modern Pharmacology, Craig, C.R., et al., (eds.), Little, Brown and Company, Boston, MA, 399 (1982). |
| | ASCHERMANN, "Restenosis after percutaneous transluminal coronary angioplasty. Pathophysiology, new trends in prevention and treatment", Cor Vasa, 36, 211-218 (1994). |
| | BAGDADE et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition", J. Clinical Endocrinology and Metabolism, 70, 1132-1135 (1990). |
| | BAQUIAL et al., "Down-Regulation of NADPH-Diaphorase (Nitric Oxide Synthase) May Account for the Pharmacological Activities of Cu(II) ₂ (3,5-Diisopropylsalicylate) ₄ ", J. Inorganic Biochem., 60, 133-148 (1995). |
| | CUNNINGHAM et al., "A Study of the Structural Basis of the Carcinogenicity of Tamoxifen, Toremifene and their Metabolites", Mutation Research, 349, 85-94 (1996). |
| | DEALVARE et al., "Mechanism of Superoxide Anion Scavenging Reaction by Bis-(Salicylato)-Copper(II) Complex", Biochemical and Biophysical Research Communications, 69, 687-694 (1976). |
| | DEHMER et al., "Reduction in the Rate of Early Restenosis After Coronary Angioplasty by a Diet Supplemented with n-3 Fatty Acids", N. Engl. J. Med., 319, 733-740 (1988). |

Examiner

Date Considered

*Substitute Disclosure Statement Form 1449-1449

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| Examiner Initials* | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
|--------------------|---|
| U | FRYE et al., "Oxolanosterol Oximes: Dual-Action Inhibitors of Cholesterol Biosynthesis", <u>Journal of Lipid Research</u> , 35, 1333-1344 (1994). |
| I | GARG et al., "Nitric Oxide-Generating Vasodilators and 8-Bromo-Cyclic Guanosine Monophosphate Inhibit Mitogenesis and Proliferation of Cultured Rat Vascular Smooth Muscle Cells", <u>Journal of Clinical Investigation</u> , 83, 1774-1777 (1989). |
| | GOODNIGHT, "The Effects of n-3 Fatty Acids on Atherosclerosis and the Vascular Response to Injury", <u>Arch. Pathol. Lab. Med.</u> , 117, 102-106 (1993). |
| | GRAINGER, "Taking Tamoxifen To Heart", <u>Nature Medicine</u> , 1, 1226 (1995). |
| | GRAINGER et al., "Tamoxifen Elevates Transforming Growth Factor- β and Suppresses Diet-Induced Formation of Lipid Lesions in Mouse Aorta", <u>Nature Medicine</u> , 1, 1067-1073 (1995). |
| | GRIGG et al., "Determinants of Restenosis and Lack of Effect of Dietary Supplementation with Eicosapentaenoic Acid on the Incidence of Coronary Artery Restenosis After Angioplasty", <u>JACC</u> , 13, 665-672 (1989). |
| | GUETTA et al., "Effects of the Antiestrogen Tamoxifen on Low-Density Lipoprotein Concentrations and Oxidation in Postmenopausal Women", <u>The American Journal of Cardiology</u> , 76, 1072-1073 (1995). |
| | GYLLING et al., "Tamoxifen Decreases Serum Cholesterol by Inhibiting Cholesterol Synthesis", <u>Atherosclerosis</u> , 96, 245-247 (1992). |
| | KEEN et al., "Hypertension Induced Alterations in Copper and Zinc Metabolism: A Link to Vascular Disease?", In: <u>Biology of Copper Complexes</u> , Sorenson, J.R.J., (ed.), Humana Press, Clifton, New Jersey, 141-153 (1987). |
| | KURAMOCHI, "Conformational Studies and Electronic Structures of Tamoxifen and Toremifene and Their Allylic Carbocations Proposed as Reactive Intermediates Leading to DNA Adduct Formation", <u>J. Med. Chem.</u> , 39, 2877-2886 (1996). |
| | MILNER et al., "Usefulness of Fish Oil Supplements in Preventing Clinical Evidence of Restenosis After Percutaneous Transluminal Coronary Angioplasty", <u>Am. J. Cardiol.</u> , 64, 294-299 (1989). |
| | O'LEARY et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and Its Use as an Index of Antioxidant Therapy", <u>Atherosclerosis</u> , 119, 169-179 (1996). |
| ✓ | REIS et al., "Randomised Trial of Fish Oil for Prevention of Restenosis After Coronary Angioplasty", <u>The Lancet</u> , 177-181 (1989). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-------------------------------------|--------------------|
| Form 1449* | Atty. Docket No.: 295.009US4 | Serial No. Unknown |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | Applicant: David J. Grainger et al. | |
| | Filing Date: Herewith | Group: Unknown |

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

| Examiner Initials* | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
|-----------------------|---|
| W | SAARTO et al., "Antiatherogenic Effects of Adjuvant Antiestrogens: A Randomized Trial Comparing the Effects of Tamoxifen and Toremifene on Plasma Lipid Levels in Postmenopausal Women with Node-Positive Breast Cancer", <u>Journal of Clinical Oncology</u> , 14, 429-433 (1996). |
| J | SORENSEN, "Pharmacological Activities of Copper Compounds", In: <u>Handbook of Metal-Ligand Interactions in Biological Fluids - Bioinorganic Medicine</u> , 2, Berton, G., (ed.), Marcel Dekker, Inc., New York, 1128-1139 (1995). |
| J | VON SCHACKY et al., "Long-Term Effects of Dietary Marine ω -3 Fatty Acids upon Plasma and Cellular Lipids, Platelet Function, and Eicosanoid Formation in Humans", <u>J. Clin. Invest.</u> , 76, 1626-1631 (1985). |
| J | WILLIAMS et al., "The Estrogen Receptor Agonist/Antagonist Tamoxifen Inhibits Progression of Coronary Artery Atherosclerosis in Monkeys", <u>Circulation</u> , 92, November 1995 AHA Meeting, (1995). |

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.